B
Bullisch
Bullisch · 25%PHAR
$11.40
Szenariopreis
$9.360
-0.262 (-2.80%)Zum Schluss
Loading chart…
- Hoch
- 9.515
- Eröffnung
- 9.500
- Volumengewichteter Durchschnittskurs
- 9.40
- Volumen
- 9.03K
- Marktkap.
- 529.32M
- Tief
- 9.310
- Umsatz
- 84.83K
- EV/EBITDA, TTM
- 35.02
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization.
KI-Analyse of Pharming Group NV (PHAR)
VerkaufenPharming Group NV is not a good buy right now due to its current price of $9.36, which is significantly below the analyst price target range of $37 to $40. Additionally, the stock has a high forward P/E ratio of 212.77, indicating overvaluation concerns. The RSI is at 30.07, suggesting the stock is oversold, but this could indicate further downside risk rather than an immediate buying opportunity.
Bewertungskennzahlen
Das aktuelle erwartete KGV von Pharming Group NV (PHAR) beträgt 212.77, verglichen mit dem 5-Jahres-Durchschnitt von -39.73.
Alphio-AI-Kursszenarien für PHAR
Szenariopreise sind das letzte monatliche Prognoseband des laufenden Jahres. Die Wahrscheinlichkeiten sind feste Modellgewichte (25 / 50 / 25), keine Garantien.
Event-Zeitleiste
News
9.010-14NewsfilterPharming Presents Positive Phase II Data for Leniolisib in Primary Immunodeficiencies
7.510-12stocktwitsBiotech Firms Set to Release Key Data This Week
9.009-25NASDAQ.COMFDA Accepts Pharming's Lower Dose Joenja Application
- 9.009-22Newsfilter
Pharming Reports Phase II Clinical Data for Leniolisib in PIDs
9.009-11NASDAQ.COMFDA Approves Joenja for Pediatric APDS Treatment
PHAR FAQ – beantwortet von Alphio AI
Pharming Group NV is a biopharmaceutical company based in the Netherlands. The Company is engaged in the development, production and commercialization of human therapeutic proteins to be used in the therapies. The Company's product portfolio is aimed at treatments for genetic disorders, blood-related disorders, infectious and inflammatory diseases, tissue and bone damage and surgical/traumatic bleeding. Its core product, RUCONEST (conestat alfa) is a recombinant human C1 esterase inhibitor approved for the treatment of acute Hereditary Angioedema (HAE) attacks in patients in Europe, the Unites States, Israel and South Korea. The product is available on a named-patient basis in other territories where it has not yet obtained marketing authorization. It operates in the Healthcare sector.
Pharming Group NV is not a good buy right now due to its current price of $9.36, which is significantly below the analyst price target range of $37 to $40. Additionally, the stock has a high forward P/E ratio of 212.77, indicating overvaluation concerns. The RSI is at 30.07, suggesting the stock is oversold, but this could indicate further downside risk rather than an immediate buying opportunity.
Community
Mehr ↗Noch keine Beiträge
Registriere dich oder melde dich an, um mitzudiskutierenDiese Seite dient nur der Recherche und ist keine Anlageberatung. Modelle können falsch liegen. Vergangene Wertentwicklung ist kein Indikator für die Zukunft.